US FDA Approves Mounjaro to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
Landmark Decision Expands the Role of Tirzepatide Beyond Blood Sugar Control
WASHINGTON / INDIANAPOLIS, August 28, 2026 — The U.S. Food and Drug Administration has approved an expanded use of Mounjaro (tirzepatide) to help reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for such complications.
The new indication marks an important development in diabetes treatment, as cardiovascular disease remains one of the most serious health concerns affecting people living with type 2 diabetes. Under the expanded approval, Mounjaro can be used to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack and non-fatal stroke, in eligible adults.
Mounjaro was originally approved in the United States in 2022 to improve blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. The medicine is administered as a prescription injection and contains tirzepatide, which acts on both GIP and GLP-1 hormone pathways involved in blood sugar regulation and appetite.
A Major Development for People With Type 2 Diabetes
The FDA's latest decision expands the importance of Mounjaro in the treatment of type 2 diabetes. For many patients, managing diabetes involves more than simply lowering glucose levels. People with type 2 diabetes can also face an increased risk of serious cardiovascular complications, including heart attack and stroke.
The newly approved cardiovascular indication means that, for eligible high-risk patients, treatment decisions may now consider both blood sugar management and the reduction of serious cardiovascular events.
The announcement also reflects a broader shift in diabetes care, with newer medicines increasingly being evaluated for their effects on the heart, kidneys, weight and other long-term health outcomes in addition to their ability to lower blood sugar.
Results From the SURPASS-CVOT Study
The expanded approval follows evidence from the large SURPASS-CVOT cardiovascular outcomes trial, which compared Mounjaro with Trulicity (dulaglutide) in adults with type 2 diabetes and established cardiovascular disease.
The study included more than 13,000 participants across 30 countries and followed patients for several years, making it the largest and longest study of tirzepatide reported by the manufacturer.
According to previously released results, Mounjaro met the trial's primary objective by demonstrating cardiovascular outcomes that were non-inferior to Trulicity. The results also showed an 8% lower rate of major adverse cardiovascular events compared with Trulicity, although the interpretation of individual findings depends on the study's statistical analysis and regulatory review.
The major cardiovascular events examined in the trial included:
Cardiovascular death
Non-fatal heart attack
Non-fatal stroke
These outcomes are particularly important because cardiovascular disease is a major cause of illness and death among people living with type 2 diabetes.
More Than a Blood Sugar Medicine
Mounjaro has already become widely known for its ability to improve blood sugar levels in adults with type 2 diabetes. Clinical studies supporting its original approval showed that tirzepatide can significantly improve HbA1c, a key measure used to assess long-term blood sugar control.
Tirzepatide works differently from medicines that target only one incretin pathway. It activates both the glucose-dependent insulinotropic polypeptide, or GIP, receptor and the glucagon-like peptide-1, or GLP-1, receptor.
These pathways play important roles in how the body responds to food and regulates blood sugar. Tirzepatide can help increase insulin release when blood glucose levels are elevated, influence appetite and food intake, and contribute to reductions in body weight in appropriate patients.
The latest FDA action further expands the medicine's role by recognizing cardiovascular risk reduction as an important treatment consideration for eligible adults with type 2 diabetes.
Why Cardiovascular Risk Matters
For people with type 2 diabetes, long-term health management can involve several connected risks. High blood sugar can occur alongside conditions such as obesity, high blood pressure, abnormal cholesterol levels and cardiovascular disease.
A heart attack or stroke can have life-changing consequences. For this reason, doctors often focus on a combination of approaches, including blood sugar management, blood pressure control, cholesterol treatment, physical activity, nutrition and, when appropriate, medicines with demonstrated cardiovascular benefits.
The new approval gives healthcare professionals another treatment option for patients who have type 2 diabetes and face a high risk of major cardiovascular events.
What the FDA Approval Means
The approval does not mean that Mounjaro is appropriate for every person with diabetes or for everyone concerned about heart disease.
The expanded indication specifically applies to adults with type 2 diabetes who meet the approved criteria and are considered at high risk for major cardiovascular events. Patients should discuss their individual medical history, current medicines and potential benefits and risks with a qualified healthcare professional.
Mounjaro remains a prescription medicine, and treatment should be based on medical advice.
Important Safety Information
Like other prescription medicines, Mounjaro can cause side effects and may not be suitable for everyone. Common adverse effects can include gastrointestinal symptoms such as nausea, diarrhea, decreased appetite, vomiting, constipation and abdominal discomfort.
The prescribing information also includes important warnings and contraindications. Mounjaro carries a boxed warning concerning thyroid C-cell tumors observed in rats, and the human relevance of those findings has not been established. The medicine is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
Patients should not start, stop or change the dose of Mounjaro without consulting a healthcare professional.
A Significant Step in the Evolution of Diabetes Care
The FDA's decision represents another major moment in the evolution of modern diabetes treatment. In the past, many diabetes medicines were evaluated primarily on their ability to reduce blood sugar. Today, clinical research increasingly examines whether treatments can also improve broader health outcomes.
The cardiovascular approval for Mounjaro highlights the growing importance of outcome-based treatment — focusing not only on laboratory numbers but also on serious complications that can affect patients' lives.
For millions of people living with type 2 diabetes, reducing the risk of heart attack, stroke and cardiovascular death remains an important medical goal.
Looking Ahead
The approval is also likely to intensify competition and innovation in the rapidly expanding market for medicines that target metabolic and cardiovascular health.
Mounjaro has already established itself as a major treatment for type 2 diabetes, and the new cardiovascular indication could further broaden its role among eligible high-risk patients. The decision follows years of clinical research examining tirzepatide's effects on blood sugar, body weight and cardiovascular outcomes.
Healthcare experts will continue to evaluate how the expanded indication affects clinical practice and which groups of patients may benefit most.
Conclusion
The FDA's approval of Mounjaro to reduce the risk of major cardiovascular events in eligible adults with type 2 diabetes represents a significant development in diabetes and cardiovascular care.
The decision expands the use of tirzepatide beyond its established role in improving blood sugar control and recognizes its potential importance in helping reduce the risk of serious events such as cardiovascular death, heart attack and stroke in high-risk patients.
For people living with type 2 diabetes, the development offers another evidence-based treatment option — but individual treatment decisions should always be made with a qualified healthcare professional who can assess a patient's complete medical history, risks and needs.
Disclaimer: This article is provided for general news and informational purposes only and does not constitute medical advice. Patients should consult a qualified healthcare professional before making decisions about prescription medicines or treatment.
